What are you searching for?

Sign in

Alexion

brand-profile-thumb

Company Headquarters

121 Seaport Blvd Boston, Massachusetts US

Driving Directions
View website

Brand Description

Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion

Key Personnel

NAME
JOB TITLE
  • Marc Dunoyer
    Chief Executive Officer
  • Soraya Bekkali
    SVP, EUCAN and International Business
  • Seng H. Cheng
    SVP, Head of Research and Product Development
  • Fred Chereau
    SVP, Strategy & Business Development
  • Sean Christie
    Chief Financial and Administration Officer
  • Ruth Diazaraque
    VP, Research and Development
  • Shane Doyle
    SVP, Head of Operations
  • Nicola Heffron
    SVP, Head of Global Marketing & Market Access
  • Christophe Hotermans
    SVP, Medical Affairs
  • Kimihiro Kasamo
    VP & General Manager, Japan
  • Simone Lauchart
    VP, Project & Portfolio Management
  • Sarah Marshall
    VP, Head of Human Resources
  • Gianluca Pirozzi
    SVP, Head of Development, Regulatory and Safety
  • Todd Spalding
    SVP, Deputy General Counsel
  • Tamar Thompson
    VP, Head of Corporate Affairs
  • Scott Weintraub
    SVP, United States Business, Alexion

Yearly results

Sales: 113.4 Billion

Headcount: 1,500
Bio/Pharma Revenues: $1,1344 (5%)
Total Revenues: $1,134 (5%)
Net Income: $2554 (6%)
R&D Budget: $2236 (3%)

Top Selling Drugs

Drug Indication $ (+/- %)
Soliris paroxysmal nocturnal hemoglobinuria (PNH) $1,134 45%

Account for 100% of total biopharma sales, same as in 2011

Sales: 783 Billion

Sales: 541 Billion

Headcount: 792
Pharma Revenues: $541 (40%)
Total Revenues: $541 (40%)
Net Income: $91 (-69%)
R&D Budget: $98 (20%)

Top-Selling Drugs in 2010

Drug

Indication

 $

(+/- %)

Soliris

paroxysmal nocturnal hemoglobinuria (PNH)

 $541 40%

Account for 100% of total biopharma sales, same as in 2009.

Previous Profile: Allergan

Sales: 387 Billion

Headcount: 12,000
Bio/pharma Revenues: $3,562 (-5%)
Total Revenues: $4,516 (-2%)
Net Income: $422 (flat)
R&D Budget: $865 (-34%)

2009 Top Selling Drugs
Drug Indication Sales (+/-%)
Cerezyme Gaucher disease $793 -36%
Renagel hemodialysis $707 +4%
Fabrazyme Fabry disease $430 -13%
Myozyme Pompe disease $325 +10%
Thymoglobulin/Lymphoglobulin transplantation $217 +19%
Thyrogen thyroid cancer $170 +15%
Aldurazyme mucopolysaccharidosis I $155 +3%
Hectorol renal disease $130 +2%

Account for 82% of total bio/pharma sales, same as in 2008.

 

 

#8 – CSL Ltd.

45 Poplar Rd., Parkville
Victoria 3052, Australia
Tel: +61 3 9389 1911
Fax: +61 3 9389 1434
www.csl.com.au

Headcount 10,000
Year Established 1916
Bio/pharma Revenues $3,211 +8%/+30%
Royalty Revenues $123 -26%/-11%
Total Revenues $3,769 +11%/+33%
Net Income $857 +36%/+63%
R&D Budget $233 +16%/+39%

 

Revenues converted at average exchange rate / based on reported currency (AUD)

 

2009 Top Selling Drugs
Drug Sales (+/-%)
Immunoglobulins $964 +41%
Plasma-derived coagulants $454 -1%
Helixate/Recombinant FVIII $369 +4%
Biotherapies (incl. Gardasil) $376 -13%

Account for 67% of total bio/pharma sales, up from 65% in 2008.

NOTE: CSL’s fiscal year runs from July 1, 2007 to June 30, 2008.

 

 

#9 – Allergan

2525 Dupont Dr.
Irvine, CA 92612
Tel: (714) 246-4500
Fax: (714) 246-4971
www.allergan.com

Headcount 8,000
Year Established 1950
Bio/pharma Revenues $1,310 flat
Total Revenues $4,504 +2%
Net Income $621 +10%
R&D Budget $706 -12%

 

2009 Top Selling Drugs
Drug Indication Sales (+/-%)
Botox furrowed brow $1,310 flat

Account for 100% of total bio/pharma sales, same as in 2008.

 

 

#10 – Alexion Pharmaceuticals

325 Knotter Dr.
Cheshire, CT 06410
Tel: (203) 272-ALXN (2596)
Fax: (203) 271-8198
www.alexionpharma.com

Headcount 650
Year Established 1992
Bio/pharma Revenues $387 +49%
Total Revenues $387 +49%
Net Income $295 +794%
R&D Budget $82 +30%

 

2009 Top Selling Drugs
Drug Indication Sales (+/-%)
Soliris paroxysmal nocturnal hemoglobinuria (PNH) $387 +49%

Account for 100% of total bio/pharma sales, same as in 2008.

 

 

Return to Top Biopharma Report homepage.

Related Content